



Mark T. Quinn, Ph.D., Professor, Department of Microbiology & Cell Biology and Director, WIMU Regional Program in Veterinary Medicine, Montana State University, Bozeman

Education:

Point Loma College, San Diego, CA; B.A.; 1982; Biology and Chemistry
University of California San Diego Extension; 1986; Professional Certificate in Management
University of California, San Diego, CA; Ph.D.; 1987; Physiology and Pharmacology
The Scripps Research Institute, La Jolla, CA; 1988-1989; Postdoctoral Research Associate

Professional Experience:

Senior Research Associate, Montana State University, 1989-1990; Assistant & Associate Research Professor, Montana State University, 1991-1995; Assistant Professor, Montana State University, 1995-1998; Associate Professor, Montana State University, 1998-2005; Interim Department Head, Montana State University, 2000-2001; Professor, Montana State University, 2005-Present; Department Head, Montana State University, 2005-2014; Director, WIMU Regional Program in Veterinary Medicine, Montana State University, 2014-present.

Honors and Awards:

National Science Foundation Graduate Fellowship (1983-1986); U.S. Public Health Service Predoctoral Traineeship (1987-1988); U.S. Public Health Service Postdoctoral Traineeship (1988-1989); Arthritis Foundation Postdoctoral Fellowship (1989-1991); Arthritis Foundation Investigator Award (1991-1993); National Institutes of Health FIRST Award (1992-1997) Charles and Nora Wiley Award for Meritorious Research (1993); Invited Speaker, Phagocyte Gordon Conference, Plymouth, NH (1993, 1997); Invited Speaker, Alberta Heritage Foundation, University of Calgary, Canada (1995); American Heart Association Established Investigator Award (1996-2001); Invited Speaker, "The Phagocyte: Molecular and Clinical Aspects," Verona, Italy (1996); Invited Member, International Bioethics Institute, Lisbon, Portugal (2000); Invited Speaker, Biochemistry of Nitric Oxide Gordon Conference, Ventura, CA (2001); Invited Speaker, ASN/ISN World Congress of Nephrology, San Francisco, CA (2001); Invited Speaker, Oxidases in Inflammation & Cellular Signaling, Cold Spring Harbor, NY (2002); Invited Speaker, NOX Family NADPH Oxidases Gordon Conference, New London, NH (2008); PI and Director, NIH P20/P30 Center of Biomedical Research Excellence in Zoonotic and Emerging Infectious Diseases (2004-2019); Invited Speaker, Purdue University, West Lafayette, IN (2015).

Professional Activities:

Member, Montana State University Institutional Review Board (1995-2000); Member, Montana State University Radiation Safety Committee (1997-2004); Member, National Arthritis Foundation Biochemistry Grant Study Section (1997-2000); Chair, Montana State University Institutional Review Board (2000-present); Member, National Arthritis Foundation Inflammation Grant Study Section (2001-2004); Member, Society for Leukocyte Biology Nominating Committee (2002, 2003); Editorial Board Member, *The Journal of Biological Chemistry* (2002-2007; 2009-2014); Member, USDA Competitive Grant Program Animal Health Study Section (2003-2005); Member, VA Merit Review Subcommittee for General Medical Sciences (2003-2006); Chair, Society for Leukocyte Biology Nominating Committee (2004, 2016); Chair, Montana State University Radiation Safety Committee (2004-2014); Member, NIH Special RFA Study Section (2004); Member, Montana State University Biosafety Committee (2004-2006); NIH ELB Study Section Ad Hoc Member (2006); USDA Animal Biosecurity Coordinated Agricultural Project Study Section (2007); Editorial Board Member, *Journal of Leukocyte Biology* (2009-Present); Member, NIH Special Emphasis Panels (2010, 2011, 2012, 2015, 2016, 2019, 2020); Society for Leukocyte Biology Scientific Council Member (2012-2015); Society for Leukocyte Biology Treasurer (2017-2019); Editorial Board, *Frontiers in Chemistry* (2019-Present).

Research Interests:

My research is focused on understanding microbicidal mechanisms utilized by innate immune cells in defense of the host against pathogens. Specific projects have focused on investigating the molecular and biochemical basis of phagocyte oxygen radical production, as well as the role of phagocyte-generated oxidants in the tissue damage associated with inflammatory diseases in humans and livestock. In recent studies, we have focused on identifying and characterizing novel immunomodulatory compounds and natural products for modulating innate immune responses, including the identification of novel classes of small-molecule agonists and antagonists that target *N*-formyl peptide receptors. We have also identified a novel class of human neutrophil elastase inhibitors and an interesting group of c-Jun *N*-terminal kinase inhibitors and are evaluating their potential as therapeutics for treating rheumatoid arthritis. Altogether, this research has contributed to 196 peer-reviewed publications, 17 review articles, and 20 book chapters.

Statement of Interest:

The Society for Leukocyte Biology (SLB) has been an integral ingredient in my career since the time I joined back during my postdoctoral years in Dr. Al Jesaitis' lab at The Scripps Research Institute. Initially, I joined so that I could receive the *Journal of Leukocyte Biology* and benefit from meeting discounts. The SLB meetings were the place where I was able to meet the real stars in the leukocyte field and helped me immensely in expanding my knowledge and collaborative connections. The meetings also reignited my excitement for my research and exposed me to new areas of leukocyte investigation. Because of this excitement and interest in the SLB, I have become more involved in the SLB, serving on the Nominating Committee, Scientific Council, and as Treasurer for the past four years. I feel that this society is the one society of all of the many scientific societies out there that has really fostered leukocyte research specifically and has provided a broad forum for leukocyte biologists studying every sort of leukocyte to support our common interest...leukocytes. Thus, I feel that my mission as SLB President, should I be elected, would be to continue to foster the development of young scientist by engaging them in the leukocyte field, enhancing their careers through relevant society interactions, and linking them with the leukocyte research pioneers who have developed the field over the years. Our society is vibrant and financially stable with an outstanding journal, and I am fortunate to have played some small part in the SLB over the years. I hope that as President I would be able to nurture continued growth of the society and continued engagement of our members in society functions and governance so that we will maintain in our current positive trajectory into the future.